Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides

被引:96
作者
Quaglino, Pietro [1 ]
Pimpinelli, Nicola [2 ]
Berti, Emilio [3 ]
Calzavara-Pinton, Piergiacomo [4 ]
Lombardo, Giuseppe Alfonso [5 ]
Rupoli, Serena [6 ]
Alaibac, Mauro [7 ]
Bottoni, Ugo [8 ,9 ]
Carbone, Angelo [10 ]
Fava, Paolo [1 ]
Fimiani, Michele [11 ]
Mamusa, Angela Maria [12 ]
Titli, Stefano [1 ]
Zinzani, Pier Luigi [13 ]
Bernengo, Maria Grazia [1 ]
机构
[1] Univ Turin, Dept Biomed Sci & Human Oncol, Dermatol Clin, I-10126 Turin, Italy
[2] Univ Florence, Dept Dermatol Sci, Florence, Italy
[3] Univ Milano Bicocca, Dermatol Clin, Milan, Italy
[4] Univ Brescia, Inst Dermatol, Brescia, Italy
[5] Immacolata Inst Dermatopathol IDI IRCCS, Div Dermatol 3, Rome, Italy
[6] Univ Ancona, Inst Haematol, Ancona, Italy
[7] Univ Padua, Unit Dermatol, Padua, Italy
[8] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Dermatol Unit, Catanzaro, Italy
[9] Univ Roma La Sapienza, Dept Dermatol, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Dept Dermatol, I-00168 Rome, Italy
[11] Univ Siena, Inst Dermatol, I-53100 Siena, Italy
[12] A Businco Reg Oncol Hosp, Haematol & Stem Cell Transplant Unit, Cagliari, Italy
[13] Univ Bologna, St Orsola Malpighi Polyclin, L&A Seragnoli Inst Hematol & Med Oncol, Bologna, Italy
关键词
mycosis fungoides; cutaneous T-cell lymphoma; prognosis; tumor-lymph node-metastasis-blood (TNMB); classification; erythroderma; tumor-stage; multivariate analysis; T-CELL LYMPHOMA; FOR-CUTANEOUS-LYMPHOMAS; SEZARY-SYNDROME; PROGNOSTIC-FACTORS; INTERNATIONAL-SOCIETY; EUROPEAN-ORGANIZATION; UNITED-STATES; IMMUNOLOGICAL FEATURES; EORTC CLASSIFICATION; TASK-FORCE;
D O I
10.1002/cncr.27627
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Mycosis fungoides (MF) is an indolent primary cutaneous T-cell lymphoma. To the authors' knowledge, no data currently are available regarding the evolution over time of the risk of developing specific pathways of disease progression. METHODS: This retrospective study analyzed 1422 patients with MF who were diagnosed and followed from 1975 through 2010 in 27 Italian Study Group for Cutaneous Lymphoma centers. The primary objectives were to ascertain the time course, pathways, and hazards risk trends of cutaneous/extracutaneous disease progression; to evaluate whether different tumor-lymph node-metastasis-blood (TNMB) stages have different pathways of disease progression; and to analyze differences between tumor-stage and erythrodermic MF with regard to clinical onset, disease evolution, and prognosis. The secondary objective was to provide a further validation for the revised International Society for Cutaneous Lymphomas and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (ISCL/EORTC) classification. RESULTS: The median follow-up was 14.5 years; stage progression occurred in 29.7% of patients and blood involvement was the most frequent extracutaneous site of disease progression. Patients with stage IA to stage IB disease demonstrated a steady low annual incidence of disease progression to tumor-stage (1%-2%); patients with stage IIA disease had a higher risk within the first years (up to 9.4%). Erythroderma evolved with a significantly higher frequency from patches/plaques (13.9%/28.2%) than tumors (P = .028 and P = .013, respectively). Hazards rates of extracutaneous involvement were low (< 1%). The T-score was found to be associated with extracutaneous involvement site, tumor-stage disease with lymph node/visceral lesions, and erythroderma with blood involvement. TNMB classification and stage progression resulted as independent prognostic variables being detected on multivariate analysis; the type of extracutaneous involvement was found to affect survival . CONCLUSIONS: The data from the current study support the need for a stage-tailored follow-up, suggest that the classification of tumor-stage disease at a stage below erythroderma could be modified, and offer a further validation for the revised TNMB classification. Cancer 2012. (c) 2012 American Cancer Society.
引用
收藏
页码:5830 / 5839
页数:10
相关论文
共 34 条
  • [1] Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sezary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
    Agar, Nita Sally
    Wedgeworth, Emma
    Crichton, Siobhan
    Mitchell, Tracey J.
    Cox, Michael
    Ferreira, Silvia
    Robson, Alistair
    Calonje, Eduardo
    Stefanato, Catherine M.
    Wain, Elizabeth Mary
    Wilkins, Bridget
    Fields, Paul A.
    Dean, Alan
    Webb, Katherine
    Scarisbrick, Julia
    Morris, Stephen
    Whittaker, Sean J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) : 4730 - 4739
  • [2] Mycosis fungoides and Sezary syndrome:: therapeutic approach and outcome in 113 patients
    Anadolu, RY
    Birol, A
    Sanli, H
    Erdem, C
    Türsen, Ü
    [J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2005, 44 (07) : 559 - 565
  • [3] Prognostic factors in Sezary syndrome: A multivariate analysis of clinical, haematological and immunological features
    Bernengo, MG
    Quaglino, P
    Novelli, M
    Cappello, N
    Doveil, GC
    Lisa, E
    De Matteis, A
    Fierro, MT
    Appino, A
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (08) : 857 - 863
  • [4] Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases
    Bradford, Porcia T.
    Devesa, Susan S.
    Anderson, William F.
    Toro, Jorge R.
    [J]. BLOOD, 2009, 113 (21) : 5064 - 5073
  • [5] BUNN PA, 1979, CANCER TREAT REP, V63, P725
  • [6] CLINICOPATHOLOGICAL AND IMMUNOLOGICAL FEATURES ASSOCIATED WITH TRANSFORMATION OF MYCOSIS-FUNGOIDES TO LARGE-CELL LYMPHOMA
    CERRONI, L
    RIEGER, E
    HODL, S
    KERL, H
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1992, 16 (06) : 543 - 552
  • [7] SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS
    COCHRAN, WG
    [J]. BIOMETRICS, 1954, 10 (04) : 417 - 451
  • [8] COX DR, 1972, J R STAT SOC B, V34, P187
  • [9] Incidence of cutaneous T-Cell lymphoma in the United States, 1973-2002
    Criscione, Vincent D.
    Weinstock, Martin A.
    [J]. ARCHIVES OF DERMATOLOGY, 2007, 143 (07) : 854 - 859
  • [10] Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
    de Coninck, EC
    Kim, YH
    Varghese, A
    Hoppe, RT
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (03) : 779 - 784